drugset
drugset / Trial / NCT06408727

Intermediate Expanded Access Protocol CNMAu8.EAP04

NCT06408727 ↗

Expanded access Temporarily not available Clene Nanomedicine National Institute of Neurological Disorders and Stroke (NINDS) · collab

Summary

An Intermediate Expanded Access Protocol (EAP) with CNM-Au8 for Amyotrophic Lateral Sclerosis for NIH Grant RFA-NS-23-012

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject CNM-Au8 Other / unclassified 30 mg —

Indications

amyotrophic lateral sclerosis